Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Ciprofloxacin.
Connection Strength

5.050
  1. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment. Int J Antimicrob Agents. 2015 Sep; 46(3):313-8.
    View in: PubMed
    Score: 0.530
  2. Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations. Int J Antimicrob Agents. 2014 Oct; 44(4):301-5.
    View in: PubMed
    Score: 0.495
  3. Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model. J Antimicrob Chemother. 2013 Apr; 68(4):881-7.
    View in: PubMed
    Score: 0.441
  4. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model. Antimicrob Agents Chemother. 2012 Mar; 56(3):1223-8.
    View in: PubMed
    Score: 0.414
  5. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. Int J Antimicrob Agents. 2008 Dec; 32(6):488-93.
    View in: PubMed
    Score: 0.330
  6. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob Agents Chemother. 2008 Jun; 52(6):1924-8.
    View in: PubMed
    Score: 0.320
  7. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model. Int J Antimicrob Agents. 2004 Aug; 24(2):173-7.
    View in: PubMed
    Score: 0.248
  8. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses. J Antimicrob Chemother. 2001 Dec; 48(6):821-6.
    View in: PubMed
    Score: 0.206
  9. Comparative activities of ciprofloxacin and levofloxacin against Streptococcus pneumoniae in an In vitro dynamic model. Antimicrob Agents Chemother. 2000 Mar; 44(3):773-4.
    View in: PubMed
    Score: 0.183
  10. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. J Antimicrob Chemother. 1999 Apr; 43(4):483-90.
    View in: PubMed
    Score: 0.171
  11. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Antimicrob Agents Chemother. 1998 Nov; 42(11):2841-7.
    View in: PubMed
    Score: 0.166
  12. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother. 1998 Mar; 42(3):659-65.
    View in: PubMed
    Score: 0.159
  13. Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically? J Chemother. 2017 Dec; 29(6):351-357.
    View in: PubMed
    Score: 0.151
  14. Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models. Antimicrob Agents Chemother. 2015 Dec 07; 60(3):1208-15.
    View in: PubMed
    Score: 0.136
  15. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration. J Antimicrob Chemother. 2016 Mar; 71(3):678-84.
    View in: PubMed
    Score: 0.136
  16. Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations. Antimicrob Agents Chemother. 2013 Oct; 57(10):4956-62.
    View in: PubMed
    Score: 0.116
  17. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis. 1991 Sep; 164(3):499-506.
    View in: PubMed
    Score: 0.101
  18. Serum inhibitory and bactericidal activity of ciprofloxacin following intravenous administration. DICP. 1989 Jun; 23(6):456-60.
    View in: PubMed
    Score: 0.087
  19. Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. Antimicrob Agents Chemother. 1987 Nov; 31(11):1782-6.
    View in: PubMed
    Score: 0.078
  20. Pharmacokinetics and pharmacodynamics of intravenous ciprofloxacin. Studies in vivo and in an in vitro dynamic model. Am J Med. 1987 Apr 27; 82(4A):363-8.
    View in: PubMed
    Score: 0.075
  21. Bactericidal activity of ciprofloxacin alone and in combination with azlocillin in an in-vitro capillary model. J Antimicrob Chemother. 1986 Nov; 18 Suppl D:49-54.
    View in: PubMed
    Score: 0.072
  22. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model. Int J Antimicrob Agents. 2005 May; 25(5):409-13.
    View in: PubMed
    Score: 0.065
  23. Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model. Int J Antimicrob Agents. 2002 Sep; 20(3):201-5.
    View in: PubMed
    Score: 0.054
  24. Bacterial strain-independent AUC/MIC and strain-specific dose-response relationships reflecting comparative fluoroquinolone anti-pseudomonal pharmacodynamics in an in vitro dynamic model. Int J Antimicrob Agents. 2002 Jul; 20(1):44-9.
    View in: PubMed
    Score: 0.054
  25. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. Int J Antimicrob Agents. 2000 Dec; 16(4):407-14.
    View in: PubMed
    Score: 0.048
  26. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrob Agents Chemother. 2000 Apr; 44(4):879-84.
    View in: PubMed
    Score: 0.046
  27. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother. 1999 Mar; 43(3):498-502.
    View in: PubMed
    Score: 0.043
  28. MIC-based interspecies prediction of the antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model. Antimicrob Agents Chemother. 1998 Nov; 42(11):2848-52.
    View in: PubMed
    Score: 0.042
  29. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob Agents Chemother. 1993 Sep; 37(9):1756-63.
    View in: PubMed
    Score: 0.029
  30. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. The European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother. 1991 May; 35(5):873-8.
    View in: PubMed
    Score: 0.025
  31. Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin. Antimicrob Agents Chemother. 1986 May; 29(5):927-9.
    View in: PubMed
    Score: 0.017
  32. Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters. Chemotherapy. 2002; 48(6):275-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.